SNRPG is a member of the Sm protein family, essential for small nuclear ribonucleoprotein (snRNP) assembly and spliceosome activation . Key interactions include:
SNRPG is a target of anti-Sm autoantibodies in systemic lupus erythematosus (SLE), serving as a diagnostic marker .
SNRPG overexpression correlates with poor outcomes in multiple cancers:
SNRPG knockdown in GBM promotes autophagy (↑ LC3-I/II ratio, Atg5/7/12 expression) .
In HCC, SNRPG co-expresses with SNRPA, SNRPB, and SNRPE (r > 0.67, p < 0.05), driving ribosome and cell cycle pathways .
Elevated in 28/33 tumors (TCGA/GTEx data), including HCC, LUAD, and glioblastoma .
Protein overexpression confirmed in 17/21 tumors (Immunohistochemistry) .
Glioblastoma: SNRPG suppression enhances temozolomide efficacy via p53-Myc axis .
HCC: SNRPG-associated pathways (ribosome biogenesis, DNA repair) are druggable vulnerabilities .
SNRPG (small nuclear ribonucleoprotein polypeptide G) is a protein-coding gene that contributes to RNA binding activity and is primarily involved in mRNA splicing via the spliceosome. It plays a critical role in RNA splicing and mRNA processing pathways . The protein is predicted to be located in the nucleus and functions as part of the SMN-Sm protein complex. SNRPG is also predicted to be active in P granules, which are cytoplasmic RNA-protein complexes involved in post-transcriptional regulation .
In zebrafish (as a model organism), SNRPG is located on chromosome 23 . In humans, the gene encodes a small protein that contains several conserved domains including:
LSM domain superfamily
Small nuclear ribonucleoprotein G
Sm domain
Sm domain, eukaryotic/archaea-type
The protein product is relatively small, with variants of approximately 70-76 amino acids in length as observed in some model systems .
SNRPG has been identified and validated as one of four stable reference genes (along with OST4, TOMM7, and NOP10) for normalizing RT-qPCR data in extracellular vesicle (EV) research . The validation process included:
Testing the stability of SNRPG expression across multiple cell lines and their secreted EVs (n=12) under various physiological and pathological conditions
Confirming its presence in human-derived biofluids (n=3)
Verifying through enzymatic treatments that SNRPG is located inside EVs rather than merely associated with their surface
Demonstrating stable detection across a range of EV subpopulations
RefFinder analysis revealed that SNRPG, OST4, TOMM7, and NOP10 exhibit greater stability compared to traditional reference genes such as HMBS, YWHAZ, SDHA, and GAPDH that were established specifically for cultured cells or tissues .
When employing SNRPG as a reference gene for RT-qPCR normalization in EV studies, researchers should:
Verify the stability of SNRPG expression in their specific experimental system before proceeding with normalization
Consider the combination of multiple reference genes (SNRPG, OST4, TOMM7, and NOP10) for more robust normalization
Implement appropriate controls to account for potential contamination in EV isolates
Perform enzymatic treatments to confirm that the RNA is truly encapsulated within EVs
Consider the influence of different (patho)physiological conditions on reference gene stability
This methodological approach helps mitigate issues related to experimental design and confounding factors that can lead to spurious associations, a common problem in genetic research as highlighted in various studies .
SNRPG expression has been found to be significantly upregulated in human glioblastoma multiforme (GBM) tissues compared to normal brain tissue, as documented in The Cancer Genome Atlas (TCGA) dataset . Specifically:
Statistical analysis using R programming language confirmed significant upregulation of SNRPG in GBM tissues (FC = 2.46, P = 3.86E-16)
Independent verification via RT-qPCR in 15 GBM tissues and non-tumor tissues corroborated these findings
Kaplan-Meier survival analyses of GBM patients with different levels of SNRPG expression revealed a correlation with patient outcomes, suggesting potential prognostic value
Research has demonstrated that downregulation of SNRPG can induce cell cycle arrest and sensitize GBM cells to temozolomide (TMZ), a standard chemotherapeutic agent used in GBM treatment . The mechanism appears to involve:
Suppression of SNRPG sensitizing GBM cells to TMZ by targeting Myc via the p53 signaling cascade
Alterations in multiple cellular pathways including cell cycle regulation, cellular assembly, development, movement, and cell death/survival
A gene expression profile analysis revealed numerous downstream targets affected by SNRPG modulation, suggesting its potential role in multiple cancer-related pathways including:
Cell cycle regulation
Cellular assembly and organization
Cellular development and movement
Cell death and survival
DNA replication
Proper experimental design is crucial for obtaining reliable results when studying SNRPG. Key considerations include:
Randomization of samples: Ensure that data collection and experimental order (e.g., plating) are randomized with respect to phenotypes of interest to avoid confounding effects
Batch effect control: Be vigilant about batch effects, particularly when combining multiple experiments (mega-analyses)
Appropriate controls: Include suitable positive and negative controls when assessing SNRPG function or expression
Validation across different models: Verify findings across multiple cell lines or tissue types to ensure generalizability
Failing to address these factors can lead to spurious associations and experimental artifacts, as observed in numerous genetic studies where approximately 95% had major problems with experimental design .
To investigate SNRPG's role in RNA processing, researchers should consider:
RNA-seq analysis: To identify global changes in splicing patterns following SNRPG modulation
Co-immunoprecipitation (Co-IP): To identify protein interaction partners within the spliceosome complex
Chromatin immunoprecipitation (ChIP): To study potential DNA-protein interactions
CRISPR-Cas9 gene editing: For precise manipulation of SNRPG expression or function
RT-qPCR with specific primer design: For detecting alternatively spliced transcripts, using the validated normalization approach with SNRPG, OST4, TOMM7, and NOP10 as reference genes
The absence of universal and stably present reference genes has hampered the application of RT-qPCR in EV studies
Traditional reference genes established for cells or tissues may not maintain stability in EVs
The small RNA content in EVs requires highly reliable normalization methods for accurate quantification
SNRPG, along with OST4, TOMM7, and NOP10, provides a solution by offering stable reference points that enable proper normalization of RT-qPCR data in EV research, facilitating both basic research and clinical applications .
SNRPG's stable presence in EVs across various conditions makes it valuable for biomarker development:
Normalization standard: Using SNRPG as a reference gene allows for accurate quantification of potential biomarker transcripts in EVs
Quality control: SNRPG detection can serve as a quality indicator for EV RNA isolation
Baseline measurement: Establishing SNRPG levels in healthy individuals provides a baseline for comparison with disease states
Longitudinal monitoring: The stability of SNRPG expression enables reliable tracking of disease progression or treatment response over time
This approach is particularly relevant for liquid biopsy applications, where EVs from biofluids offer a non-invasive window into disease processes.
Recent investigations have begun to explore non-canonical roles of SNRPG:
Cancer biology: Beyond GBM, examining SNRPG's role in other cancer types could reveal common mechanisms of dysregulation
Therapeutic targeting: Exploring SNRPG as a potential therapeutic target, particularly in cancers where it is upregulated
Structural biology: Determining high-resolution structures of SNRPG-containing complexes to better understand its mechanistic functions
Developmental biology: Investigating the role of SNRPG in cellular differentiation and development
Systems biology: Mapping SNRPG's position in broader regulatory networks affecting RNA metabolism
When encountering contradictory findings about SNRPG function, researchers should:
Evaluate experimental contexts: Different cell types, developmental stages, or physiological conditions may explain divergent results
Consider technical variations: Different methodologies (knockout vs. knockdown, acute vs. chronic depletion) may yield different outcomes
Examine dose-dependency: SNRPG may have different effects at different expression levels
Explore compensatory mechanisms: Other spliceosomal components may compensate for SNRPG alterations in some systems but not others
Integrate multi-omics data: Combining transcriptomic, proteomic, and functional data can provide a more complete picture of SNRPG's role
SNRPG is involved in the splicing of U12-type introns in pre-mRNAs and is also a part of the U7 snRNP, which participates in the processing of the 3’ end of histone transcripts . The protein encoded by this gene is essential for the proper functioning of the spliceosome, a complex responsible for removing introns from pre-mRNA transcripts .
The SNRPG gene is located on chromosome 2 and has several transcript variants encoding different isoforms . It is associated with various pathways, including the processing of capped intron-containing pre-mRNA and capped intronless pre-mRNA . Diseases associated with SNRPG include Cardiomyopathy, Dilated, 1Dd, and Spinal Muscular Atrophy .
Human recombinant SNRPG is used in various research applications to study its role in mRNA splicing and its involvement in different genetic pathways. Understanding the function and structure of SNRPG can provide insights into the mechanisms of gene expression regulation and the development of certain diseases.